UroGen Pharma (URGN) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Nasdaq slides over 1% as Alphabet results revive AI spending fears
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts URGN Hot Sheet
Join SI Premium – FREE
UroGen Pharma (NASDAQ: URGN) reported Q3 EPS of ($1.13), $0.03 better than the analyst estimate of ($1.16). Revenue for the quarter came in at $16.01 million versus the consensus estimate of $20.15 million.
For earnings history and earnings-related data on UroGen Pharma (URGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stagwell Inc (STGW) Tops Q3 EPS by 3c ; Offers Guidance
- UroGen's Jelmyto shows durable response in 5-year cancer study
- Exlservice (EXLS) PT Raised to $48 at Stifel
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
